Partner Content Partner Content 3rd Annual Antibody Summit: Bispecifics & Multispecifics We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria.
Views & Analysis Harnessing RWE in rare diseases Ahead of eyeforpharma Philadelphia 2019, Sonal Bhatia, Pfizer’s vice president, North America medical lead, rare disease talked to us about the importance of collaboration and RWE to he
Partner Content Partner Content 3rd Annual Aseptic Processing Summit Vonlanthen Group is pleased to invite you to the 3rd Annual Aseptic Processing Summit scheduled on November 20-21, in Vienna, Austria.
Partner Content Partner Content 3rd Annual Impurities: Genotoxic and Beyond Summit We are pleased to invite you to the 3rd Annual Impurities: Genotoxic and Beyond Summit scheduled for June 12th-13th, 2019.
News AZ's Fasenra also works in rare organ damage diseases AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown.
News Alexion signs R&D deals with two Nordic biotechs Alexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends